Latest Updates
-
Drishyam: The Conclusion — Everything You Need To Remember Before Watching The New Film -
Jantar Mantar Protest On Gandhi Jayanti 2026: Why This Delhi Landmark Is A Hub For Public Demonstrations -
World Smile Day 2026: 5 Ways Smiling May Benefit Your Health And Support Everyday Wellbeing -
Lal Bahadur Shastri Jayanti 2026: 10 Quotes That Reflect His Ideas On Leadership, Peace And Nation-Building -
Gandhi Jayanti 2026: 10 Places In India Where You Can Experience Mahatma Gandhi’s Legacy -
International Day Of Non-Violence 2026: Why Was Gandhiji's Birthday Chosen For A Global Message Of Peace? -
Saptami Shraddha 2026: Who Should Perform It And What Does This Pitru Paksha Ritual Mean? -
Gandhi Jayanti 2026: 7 Sustainable Lifestyle Lessons We Can Still Learn From Gandhi -
Who Is Captain Smit Machchhar? The Pilot Who Fought Back Mid-Air on Flydubai FZ1073 -
Toys For Kidults And ToyTrends: Inside The Spielwarenmesse 2027 Preview
Each Dose Of Covishield, Covaxin Likely To Be Capped At Rs 275 After Getting Regular Market Approval

The price of Covishield and Covaxin, the COVID-19 vaccines which are expected to soon get regular market approval from India's drug regulator, is likely to be capped at Rs 275 per dose plus an additional service charge of Rs 150, official sources said. According to them, the National Pharmaceutical Pricing Authority (NPPA) has been directed to start working towards capping the price to make the vaccines affordable.
As of now, Covaxin is priced at Rs 1,200 per dose while Covishield costs Rs 780 in private facilities. The prices include Rs 150 service charge. Both the vaccines are only authorised for emergency use in the coAn Subject Expert Committee on COVID-19 of the Central Drugs Standard Control Organisation on January 19 recommended granting regular market approval to COVID vaccines Covishield and Covaxin for use in the adult population subject to certain conditions.
"The NPPA has been asked to work towards capping the price of the vaccines. The price is likely to be capped at Rs 275 per dose along with an additional service charge of Rs 150," an official source said.
Prakash Kumar Singh, the director (government and regulatory affairs) at Serum Institute of India, had submitted an application to the Drugs Controller General of India on October 25 seeking regular market approval for its Covishiled vaccine.
A couple of weeks ago, V Krishna Mohan, the whole-time director at Bharat Biotech, submitted complete information on the chemistry, manufacturing and controls, along with the pre-clinical and clinical data while seeking regular market authorisation for Covaxin.
Covaxin and Covishield were granted Emergency Use Authorisation (EUA) on January 3 last year.
COVID vaccine - Photo by DW News / Getty Images.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications
